Protein rab3 GEP

Abstract: The present invention provides a protein Rab3 GEP which is a GDP/GTP exchange protein active on the Rab3 subfamily small G proteins, which has an amino acid sequence of Sequence ID No. 1 or an amino acid sequence substantially the same as that of the Sequence ID No. 1, a cDNA sequence coding this protein, and genomic DNA sequence to which the cDNA sequence or a part thereof hybridizes. According to the invention, there is provided a novel protein (Rab3 GEP) specific for the Rab3 subfamily small G proteins which are involved in intercellular vesicle trafficking, and a genetic material for industrial utilization thereof. This protein is useful, not only for clarification of the molecular mechanism of intracellular vesicle trafficking which is an important cellular event, but also for development of diagnosis, prevention and therapy of neural diseases and the like.

Description: Field of the Invention The present invention relates to a GDP/GTP exchange protein (GEP) specific for the Rab3 subfamily small GTP-binding proteins (G proteins). More particularly, the present invention relates to the protein Rab3 GEP useful for clarification of a molecular mechanism of intracellular vesicle trafficking essential for maintenance of homeostasis of a living organism, or for diagnosis or development of preventive and therapeutic drugs for neural diseases. Description of the Related Art In a general cell composing a living organism, there exist a number of organelles surrounded by unit membranes, such as endoplasmic reticulum, Golgi complex, lysosome, and endosome, and material transport between these organelles is accomplished by accurate trafficking of vesicles (intracellular vesicle trafficking). For instance, membrane receptors, such as EGF and PDGF receptors, are synthesized on ribosomes and transported to the endoplasmic reticulum membrane from where they are transported to the plasma membrane through the Golgi complex by vesicles. Soluble substances, such as those secreted outside the cell from the plasma membrane, are also transported by vesicles. For instance, hormones and digestive enzymes are synthesized on ribosomes and transported to the endoplasmic reticulum lumen from where they are transported to the plasma membrane. Exocytosis, endocytosis, and transcytosis are performed by intracellular vesicle trafficking. There are two exocytotic pathways: one is a regulated pathway and the other is a constitutive pathway. In the former pathway, in most cases exocytosis is regulated by Ca 2+ . Intracellular vesicle trafficking is also involved in various other cell functions, such as formation of cell polarity, cytokinesis and cell motility. Although intracellular vesicle trafficking is one of the very important cellular events as described above, the molecular mechanism has not as yet been completely clarified. The mechanism of intracellular trafficking clarified so far is as follows. There are at least four principal mechanisms in intracellular vesicle trafficking: (i) budding of the vesicle from the donor membrane; (ii) targetting of the vesicle to the acceptor membrane; (iii) docking of the vesicle to the acceptor membrane; (iv) fusion of the vesicle with the acceptor membrane. The vesicle trafficking is regulated by the Rab family small G proteins. There are approximately thirty members in the Rab family and each member is located in each membrane compartment and exerts its specific function. The mode of action of the Rab family members in the targetting and docking processes in intracellular vesicle trafficking is as follows: the GDP-bound inactive form of each Rab family member is complexed with Rab GDP dissociation inhibitor (GDI) and remains in the cytoplasm. When it is released from Rab GDI, GEP exerts its action, and the Rab family member is converted to the GTP-bound active form. This GTP-bound form binds to its specific target protein on the vesicle, which is consequently transported to the acceptor membrane. Before or after fusion of the vesicle with the membrane, the GTP-bound form is converted to the GDP-bound form. Once the GDP-bound form is produced on the membrane, it is complexed with Rab GDI and translocated from the membrane to the cytoplasm. On the other hand, the present inventors have discovered Rab3A as a member of the Rab family small G proteins (J. Biol. Chem., 263:2879-2904, 1998), and revealed that Rab3A plays an important role in Ca 2+ -dependent exocytosis, particularly in neurotransmitter release (Int. Rev. Cytol., 133: 187-230, 1992). They have further found Rab GDI, a regulatory protein of Rab3A (J. Boil. Chem. , 265: 2333-2337, 1990) and Rabphilin3A, a target protein of Rab3A (Mol. Cell. Biol., 13: 2061-2068, 1993). In intracellular vesicle trafficking, as described above, the mode of action of the Rab family members has been clarified, and the research efforts made by the present inventors have permitted specification of regulatory proteins and target proteins of the Rab family members. However, in order to understand the more detailed mechanism of intracellular vesicle trafficking, it is indispensable to find GEP and GAP specific for each Rab family member or Rab subfamily. At least, no GEP or GAP specific for the Rab3 subfamily members (Rab3A, -B, -C and -D) has not as yet been identified. Two GEPs for Rab3A, Mss4 (Nature, 361: 464-467, 1993) and Rab3A GRF (J. Boil. Chem., 267: 22715-22718, 1992) have been so far found: the former is not specific for the Rab3 subfamily, and the latter has been just partially purified and its primary structure has not been reported. Summary of The Invention The present invention has an object to provide a novel protein (Rab3 GEP) specific for the Rab3 subfamily small G proteins involved in intracellular vesicle trafficking, in a state that the structure (amino acid sequence) and properties thereof have not been clarified. Another object of the invention is to provide a material for genetic engineering manipulation of this Rab3 GEP. The invention provides a protein Rab3 GEP, which is a GDP/GTP exchange protein specific for the Rab3 subfamily small G proteins, and comprises the amino acid sequence of Sequence ID No. 1. In addition, the invention provides a cDNA sequence encoding the amino acid sequence of the Sequence ID No. 1. The invention also provides a genomic DNA sequence to which the cDNA set forth above or a part thereof is hybridized. According to the invention, there is provided a novel protein (Rab3 GEP) specific for the Rab3 subfamily small G proteins involved in intracellular vesicle trafficking, and a genetic material for industrially utilizing such a protein. This protein is useful not only for clarifying the molecular mechanism of intracellular vesicle trafficking which is an important cellular event, but also for developing diagnosis, prevention and therapy of neural diseases. Brief Description of The Drawings Fig. 1 illustrates the column chromatographies: (A) shows Superdex 200 column chromatography, and (B) shows the second hydroxyapatite column chromatography ( represents the [3H]GDP bound which is an indicator of Rab3 GEP activity, ---, absorbance at 280 nm, and the lower panels illustrate SDS-polyacrylamide gel electrophoresis (PAGE) analysis with silver staining); Fig. 2 illustrates the substrate specificity of Rab3 GEP II (A-1, B-1) and Mss4 (A-2, B-2): (A-1, A-2) Rab3A (), Rab2 (Δ ), Rab5A (○), Rab10 (▴ ) and Rab11 (▪ ); and (B-1, B-2) Rab3A (), Rab3B (Δ ), Rab3C (▴ ), Rab3D (○); and Fig. 3A illustrates the requirement of Rab3 GEP II (A-1) and Mss4 (A-2) for lipid modifications of Rab3A representing their activity to lipid-modified Rab3A () and lipid-unmodified Rab3A (○); and Fig. 3B illustrates the sensitivity of Rab3 GEP II and Mss4 to Rab GDI (with Rab3 GEP II (), with Mss4 (▴ ), without Rab3 GEP II or Mss4 (○)) Detailed Description of The Invention A protein Rab3 GEP of the invention is purified from rat brain synaptic soluble fraction through successive column chromatographies by using lipid-modified Rab3A as a substrate, and has a molecular weight of about 200 kD as estimated by SDS-PAGE (about 270 kD as estimated by gel filtration). A cDNA clone was obtained from a rat cDNA library with partial amino acid sequences of this purified protein as probes, and the cDNA amino acid sequence was analyzed. This protein Rab3 GEP was confirmed to have the amino acid sequence of Sequence ID No. 1. Therefore, Rab3 GEP of the invention is available by inserting the foregoing cDNA into an appropriate expression vector, and expressing the cDNA in Escherichia coli and the like. A protein derived from other animals than rat can be obtained by a process, for example, of isolating a cDNA from the cDNA library of the animal by using the cDNA of the invention or a part thereof as a probe, and causing expression in a suitable host-vector system. The thus obtained protein derived from an animal other than rat also has an amino acid sequence substantially the same as that of Sequence ID No. 1. The cDNA sequence of the invention includes, as described above, cDNA of rat or cDNA coming from any animal other than rat. The genomic DNA sequence of the invention include DNA sequence of any of all the animal species. Examples A protein Rab3 GEP of the invention will be described further in detail by means of Examples. The invention is not however limited by the following examples. Example 1: Purification of Rab3 GEP Synaptic soluble fraction was prepared from 80 rat brains. A half of the fraction (500 ml, 455 mg of protein) was adjusted to 0.2 M NaCl and applied to a Q-Sepharose FF column (2.6 x 10 cm) equilibrated with Buffer A (20 mM Tris/Cl at pH 7.5 and 1 mM DTT) containing 0.2 M NaCl. Elution was performed with 350 ml of Buffer A containing 0.5 M NaCl. Fractions of 10 ml each were collected. When the Rab3 GEP activity was assayed by measuring the dissociation of [ 3 H]GDP from lipid-modified Rab3A, the activity was observed in Fractions 5-19. These fractions (150 ml, 159 mg of protein) were collected, and NaCl was added to give a final concentration of 2 M. The sample was applied to a phenyl-Sepharose column (2.6 x 10 cm) equilibrated with Buffer A containing 2 M NaCl. Elution was performed with a 360-ml linear gradient of NaCl (2-0 M) in Buffer A, followed by 180 ml of Buffer A. Fractions of 6 ml each were collected. The Rab3 GEP activity was observed in Fractions 52-63. These fractions (72 ml, 8. 6 mg of protein) were collected and applied to a hydroxyapatite column (1.0 x 30 cm) equilibrated with Buffer B (20 mM potassium phosphate at pH 7.8, 1 mM DTT, 0.6% CHAPS, and 10% glycerol). Elution was performed with a 75-ml linear gradient of potassium phosphate (20-100 mM) in Buffer B and a subsequent 75-ml linear gradient (100-300 mM) in Buffer B, followed by a 50-ml linear gradient (300-500 mM) in Buffer B. Fractions of 2.5 ml each were collected. The Rab3 GEP activity was observed in Fractions 46-54. These fractions (22.5 ml, 2.2 mg of protein) were collected, mixed with an equal volume of Buffer C (20 mM bis-Tris/Cl at pH 5.5, 0.5 mM EDTA, 1 mM DTT, 0.6% CHAPS, and 10% glycerol), and applied to a MonoQ HR 10/10 column equilibrated with Buffer C. Elution was performed with a 60-ml linear gradient of NaCl (0.2-0.5 M) in Buffer C. Fractions of 1 ml each were collected. The Rab3 GEP activity was observed in Fractions 24-33. These fractions (10 ml, 0.44 mg of protein) were collected, concentrated to about 2 ml, and applied to a Superdex 200 column (1.6 x 60 cm) equilibrated with Buffer D (20 mM Tris/Cl at pH 7.5, 0.5 mM EDTA, 1 mM DTT, 0.6 % CHAPS, 0.45% sodium cholate, 10% glycerol, and 0.15 M NaCl). Elution was performed with the same Buffer. Fractions of 2 ml each were collected. The Rab3 GEP activity appeared in Fractions 26-30 (Fig 1A, arrowhead). These active fractions (10 ml, 45 mg of protein) were collected. The other half of the synaptic soluble fraction was also subjected to the successive column chromatographies in the same manner as described above. The active fractions of the two Superdex 200 column chromatographies were combined and applied to a high pressure liquid chromatography hydroxyapatite column equilibrated with Buffer B. Elution was performed with a 12.5-ml linear gradient of potassium phosphate (20-100 mM) in Buffer B, followed by a 50-ml linear gradient of potassium phosphate (100-500 mM) in Buffer B. Fractions of 1 ml each were collected. The Rab3 GEP activity appeared in two peaks (Fig 1B, arrowhead) in Fraction 29-33 and 34-38 (Fig. 1B). The first (5 ml, 15.5 mg of protein) and second (5 ml, 7.5 mg of protein) peaks were separately collected as Rab3 GEPI and Rab3 GEPII, respectively, and stored at -80°C. This Rab3 GEPII was found to be inactive on the other Rab families (Rab2, Rab5A, Rab10 and Rab11) (Fig. 2A). Rab3 GEPII was active on Rab3A and Rab3C, partially on Rab3D, but was almost inactive on Rab3B (Fig. 2B). Further, while Rab3 GEPII was active on lipid-modified Rab3A, it was inactive on lipid-unmodified Rab3A (Fig. 3A). These properties of Rab3 GEPII were different from those of protein Mss4 which was equally active on lipid-modified and -unmodified Rab3A and active on many other Rab family members (Figs. 2 and 3) , whereas both Rab3 GEPII and Mss4 were inactive to Rab3A complexed with Rab GDI (Fig. 3B). Rab3 GEPI had almost the same properties as those of Rab3 GEPII. Example 2: Peptide mapping of Rab3 GEP and cloning of its cDNA thereof Rab3 GEPII (20 mg of protein) and Rab3 GEPI (10 mg of protein) purified in the same manner as in Example 1 were separately subjected to SDS-PAGE (6.5% polyacrylamide gel). Each protein band corresponding to a protein with a molecular weight of about 200 kD was isolated from the gel, digested completely with a lysyl endopeptidase, and subjected to C18 reverse phase high pressure liquid chromatography. The sequences of the nine peptides were determined with a peptide sequencer. To determine the N-terminal amino acid sequence of Rab3 GEPII, purified GEPII (4 mg of protein) was applied to SDS-PAGE, and transferred to a PVDF membrane. The protein band was cut from the membrane and directly subjected to the peptide sequencer. A rat brain cDNA library was screened using the oligonucleotide probes designed from the partial amino acid sequences and a cDNA of Rab3 GEPII was cloned. The sequence of this cDNA was determined in accordance with a known method using a DNA sequencer (ABI373), and the amino acid sequence (sequence No. 1) of Rab3 GEPII was determined from the resultant nucleotide sequence. As a result of homology retrieval by computer, this amino acid sequence exhibited 35% identity with a protein encoded by cDNA yk26g7.5 of Caenorhabditis elegans. While it was almost identical to a protein encoded by human DENN, the human DENN protein lacked about C-terminal 300 amino acids of Rab3 GEP. Example 3: Expression of recombinant Rab3 GEP The cDNA of Rab3 GEP was inserted into the pCMV vector, and the construct was transfected into COS7 cells by the DEAE-dextran method. The COS7 cells were homogenized with a buffer (20 mM Tris/Cl at pH 7.5, 1 mM DTT, and 0.6% CHAPS) and centrifuged at 100,000 x g for 1 hr. The supernatant (2 ml, 4.2 mg of protein) was applied to a Mono Q PC1.6/5 column chromatography. The Rab3 GEP activity of each fraction was measured, and the active fractions were used as recombinant Rab3 GEP. This recombinant Rab3 GEP had the same properties (requirement for lipid modifications of Rab3A, substrate specificity and sensitivity to Rab GDI) as those of the foregoing purified Rab3 GEPII. Northern blot and Western blot analyses indicated that Rab3 GEP was expressed in all the rat tissues (heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis) with the highest expression in brain. Sequence Listing Sequence ID No.:1 Length:1602 amino acids Type: protein Sequence

Claims: A GDP/GTP exchange protein specific for the Rab3 subfamily G proteins, which comprises the amino acid sequence of Sequence ID No. 1. A cDNA sequence coding the amino acid sequence of the Sequence ID No. 1.

Inventors: NAKANISHI HIROYUKI, TAKAI YOSHIMI, WADA MANABU, NAKANISHI, HIROYUKI, TAKAI, YOSHIMI, WADA, MANABU
Applicants: JAPAN CHEM RES, JAPAN SCIENCE & TECH CORP, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, JCR PHARMACEUTICALS CO., LTD.
Application year: 1998
Main classification: C12N15
IPC codes: C12N15, C07K14, C12P21, A61K38, C12R1